# Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)

> **NCT04923802** · — · TERMINATED · sponsor: **GeneCast Biotechnology Co., Ltd.** · enrollment: 13 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Neoantigen
- Next-generation Sequencing
- Biomarker

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04923802
- **Lead sponsor:** GeneCast Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-24
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Unable to recruit sufficient numbers of patients
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04923802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04923802, "Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04923802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*